Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenusGENSF 71 EV-to-OCF is 20.40 as of Sep. 15, 2026, which is 53% below its 10-year median of 43.54. GuruFocus rates GENSF with a GF Score™ of 71/100 and a GF Value™ of $28.90. The stock has 4 warning signs investors should review. Among 1,405 Biotechnology companies, Genus ranks worse than 88.54% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Genus's Enterprise Value is $2,025.9 Mil.
Genus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $99.3 Mil. Therefore, Genus's EV-to-OCF for today is 20.40.
The historical rank and industry rank for Genus's EV-to-OCF or its related term are showing as below:
GENSF'
s EV-to-OCF Range Over the Past 10 Years
Min: 19.08 Med: 43.54 Max: 72.73
Current: 20.16
During the past 13 years, the highest EV-to-OCF of Genus was 72.73. The lowest was 19.08. And the median was 43.54.
GENSF's EV-to-OCF is ranked worse than 88.54% of 1405
companies
in the Biotechnology industry
Industry Median: -3.38
vs GENSF: 20.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-15), Genus's stock price is $31.065.
Genus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $5.671. Therefore, Genus's PE Ratio (TTM) for today is 5.48.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genus's share price for today is $31.065.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $5.671.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genus EV-to-OCF Related Terms
Genus EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Genus's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genus's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Genus's EV-to-OCF falls into.
Genus's current Enterprise Value is $2,025.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $99.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genus (GENSF) has a EV-to-OCF of 20.40 as of Sep. 15, 2026. This is 53% below median its historical median of 43.54. Over the past decade, Genus' EV-to-OCF has ranged from 19.08 to 72.73. According to the industry distribution chart, Genus ranks #1244 out of 1405 companies in the Biotechnology industry, placing it in the top 88.5%.
Is Genus' EV-to-OCF too high?
Genus' current EV-to-OCF of 20.40 is 53% below median its 10-year median of 43.54. Over the past 10 years, this metric has ranged from a low of 19.08 to a high of 72.73. Based on the distribution chart, Genus ranks #1244 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genus has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Genus' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #1244 out of 1405 companies for EV-to-OCF. This places Genus in the lower half of its industry. Historically, Genus' own EV-to-OCF has ranged from 19.08 to 72.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Genus's current EV-to-OCF is 20.40, which is 53% below median its own 10-year median of 43.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Genus (GENSF) has a current EV-to-OCF of 20.40. The stock's GF Value™ is $28.90, compared to a current price of $31.07 — trading 7.5% above its estimated fair value. The current EV-to-OCF is 20.40, which is 53% below median its 10-year median of 43.54. Genus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Genus (GENSF), the current EV-to-OCF is 20.40 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (GENSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of $31.07 is trading 7.5% above its estimated GF Value™ of $28.90.
Key valuation signals for GENSF:
EV-to-OCF: 20.40 (53% below median its 10-year median of 43.54)
GF Value™: $28.90 vs. price of $31.07 (7.5% above fair value)
No single metric tells the full story. See the GENSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
71GF Score
Get the complete analysis for GENSF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENSF has been successfully added to your 
